vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $19.2M, roughly 1.9× CuriosityStream Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -19.7%, a 16.0% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs 33.4%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-5.8M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs 17.0%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

CURI vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.9× larger
GYRE
$37.2M
$19.2M
CURI
Growing faster (revenue YoY)
CURI
CURI
+2.4% gap
CURI
35.8%
33.4%
GYRE
Higher net margin
GYRE
GYRE
16.0% more per $
GYRE
-3.7%
-19.7%
CURI
More free cash flow
CURI
CURI
$9.7M more FCF
CURI
$3.9M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
CURI
CURI
Annualised
CURI
26.5%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
GYRE
GYRE
Revenue
$19.2M
$37.2M
Net Profit
$-3.8M
$-1.4M
Gross Margin
95.3%
Operating Margin
-17.6%
0.3%
Net Margin
-19.7%
-3.7%
Revenue YoY
35.8%
33.4%
Net Profit YoY
-34.6%
-340.1%
EPS (diluted)
$-0.07
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
GYRE
GYRE
Q4 25
$19.2M
$37.2M
Q3 25
$18.4M
$30.6M
Q2 25
$19.0M
$26.8M
Q1 25
$15.1M
$22.1M
Q4 24
$14.1M
$27.9M
Q3 24
$12.6M
$25.5M
Q2 24
$12.4M
$25.2M
Q1 24
$12.0M
$27.2M
Net Profit
CURI
CURI
GYRE
GYRE
Q4 25
$-3.8M
$-1.4M
Q3 25
$-3.7M
$5.9M
Q2 25
$784.0K
$1.6M
Q1 25
$319.0K
$3.7M
Q4 24
$-2.8M
$569.0K
Q3 24
$-3.1M
$2.9M
Q2 24
$-2.0M
$4.5M
Q1 24
$-5.0M
$9.9M
Gross Margin
CURI
CURI
GYRE
GYRE
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
CURI
CURI
GYRE
GYRE
Q4 25
-17.6%
0.3%
Q3 25
-24.5%
22.7%
Q2 25
2.5%
8.1%
Q1 25
0.5%
10.3%
Q4 24
-27.4%
2.4%
Q3 24
-25.8%
16.6%
Q2 24
-20.6%
12.7%
Q1 24
-30.4%
29.7%
Net Margin
CURI
CURI
GYRE
GYRE
Q4 25
-19.7%
-3.7%
Q3 25
-20.4%
19.4%
Q2 25
4.1%
5.9%
Q1 25
2.1%
16.9%
Q4 24
-19.9%
2.0%
Q3 24
-24.3%
11.2%
Q2 24
-16.4%
18.0%
Q1 24
-42.0%
36.6%
EPS (diluted)
CURI
CURI
GYRE
GYRE
Q4 25
$-0.07
$-0.01
Q3 25
$-0.06
$0.03
Q2 25
$0.01
$0.00
Q1 25
$0.01
$0.00
Q4 24
$-0.05
$0.00
Q3 24
$-0.06
$0.01
Q2 24
$-0.04
$0.01
Q1 24
$-0.09
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$27.3M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$106.0M
Total Assets
$75.7M
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
GYRE
GYRE
Q4 25
$27.3M
$52.4M
Q3 25
$27.8M
$60.0M
Q2 25
$28.1M
$54.4M
Q1 25
$33.4M
$29.9M
Q4 24
$32.1M
$26.7M
Q3 24
$33.2M
$25.1M
Q2 24
$39.5M
$25.1M
Q1 24
$38.8M
$37.4M
Stockholders' Equity
CURI
CURI
GYRE
GYRE
Q4 25
$41.5M
$106.0M
Q3 25
$47.2M
$101.9M
Q2 25
$49.8M
$92.0M
Q1 25
$58.1M
$68.1M
Q4 24
$57.8M
$63.3M
Q3 24
$62.2M
$63.2M
Q2 24
$64.8M
$60.4M
Q1 24
$67.0M
$56.6M
Total Assets
CURI
CURI
GYRE
GYRE
Q4 25
$75.7M
$166.1M
Q3 25
$74.7M
$159.4M
Q2 25
$78.7M
$152.6M
Q1 25
$85.3M
$129.8M
Q4 24
$86.2M
$125.4M
Q3 24
$87.6M
$125.2M
Q2 24
$90.9M
$120.9M
Q1 24
$94.6M
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
GYRE
GYRE
Operating Cash FlowLast quarter
$4.0M
$-5.6M
Free Cash FlowOCF − Capex
$3.9M
$-5.8M
FCF MarginFCF / Revenue
20.5%
-15.5%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
GYRE
GYRE
Q4 25
$4.0M
$-5.6M
Q3 25
$4.4M
$4.7M
Q2 25
$2.8M
$2.1M
Q1 25
$1.9M
$-129.0K
Q4 24
$3.0M
$-2.8M
Q3 24
$2.3M
$1.7M
Q2 24
$2.2M
$-5.5M
Q1 24
$666.0K
$2.9M
Free Cash Flow
CURI
CURI
GYRE
GYRE
Q4 25
$3.9M
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$1.8M
$-251.0K
Q4 24
$-2.8M
Q3 24
$1.0M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
CURI
CURI
GYRE
GYRE
Q4 25
20.5%
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
12.2%
-1.1%
Q4 24
-10.1%
Q3 24
4.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
CURI
CURI
GYRE
GYRE
Q4 25
0.1%
0.4%
Q3 25
0.0%
2.2%
Q2 25
0.0%
1.0%
Q1 25
0.5%
0.6%
Q4 24
0.0%
0.2%
Q3 24
0.0%
2.7%
Q2 24
0.0%
5.8%
Q1 24
0.0%
0.9%
Cash Conversion
CURI
CURI
GYRE
GYRE
Q4 25
Q3 25
0.79×
Q2 25
3.56×
1.32×
Q1 25
6.03×
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons